Physician profile
Niraj D Jani
NPI 1386673671
$214,170.40
in general payments reported to CMS, 2019-2025
51 companies · $49K in 2025
The $49K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $9,229 · 2021: $17K · 2022: $20K · 2023: $15K · 2024: $81K · 2025: $49K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Travel and Lodging: $19K · Food and Beverage: $18K · Consulting Fee: $4,230 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $103,550.00 |
| Travel and Lodging | $18,868.24 |
| Food and Beverage | $18,147.97 |
| Consulting Fee | $4,230.00 |
| Education | $108.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $75,949.25 | 2019-2025 | |
| Phathom Pharmaceuticals, INC. | $74,012.39 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $18,348.30 | 2020-2023 | |
| Allergan, INC. | $13,609.84 | 2019 | |
| Aimmune Therapeutics, INC. | $10,925.69 | 2023-2025 | Zenpep |
| Madrigal Pharmaceuticals | $5,391.71 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $2,857.55 | 2019-2025 | Axios, Exalt Model D, General - Metal Stents - G.I. |
| Takeda Pharmaceuticals U.S.A., INC. | $1,887.63 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Janssen Biotech, INC. | $1,656.72 | 2019-2025 | Tremfya, Stelara, Simponi |
| Medtronic, INC. | $1,628.66 | 2021-2023 | Endoflip |
| Pfizer INC. | $1,150.65 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $773.70 | 2021-2025 | Xifaxan, Trulance |
| Genzyme Corporation | $745.22 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $668.37 | 2022-2025 | Dupixent |
| Celgene Corporation | $665.36 | 2021-2024 | Zeposia |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $335.37 | 2022-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $296.35 | 2023-2025 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $276.49 | 2024-2025 | Iqirvo |
| Daiichi Sankyo INC. | $248.56 | 2019-2024 | Injectafer |
| Ironwood Pharmaceuticals, INC | $224.35 | 2019-2024 | Linzess |
| Gilead Sciences, INC. | $212.58 | 2021-2025 | |
| Qol Medical, LLC | $201.18 | 2023-2024 | Sucraid, Sucraid |
| Celltrion USA INC. | $188.92 | 2024-2025 | Vegzelma, Zymfentra |
| Evoke Pharma, INC. | $181.14 | 2023-2025 | Gimoti |
| Janssen Scientific Affairs, LLC | $157.05 | 2021-2024 | Tremfya |
| Lilly USA, LLC | $155.42 | 2024-2025 | Omvoh |
| Mallinckrodt Hospital Products INC. | $142.17 | 2024-2025 | Terlivaz |
| Covidien LP | $124.07 | 2019 | |
| Amgen INC. | $122.74 | 2020-2025 | Avsola, Uplizna, Amjevita |
| Ferring Pharmaceuticals INC. | $122.37 | 2022-2023 | Rebyota |
| E.R. Squibb & Sons, L.L.C. | $110.00 | 2022 | |
| Olympus America INC. | $85.58 | 2019-2024 | Hanarostent Esophagus Tts(Ccc), Endoclot Phs |
| Organon LLC | $82.60 | 2023-2025 | Renflexis, Hadlima |
| Merck Sharp & Dohme LLC | $82.24 | 2021-2023 | Dificid, Zinplava |
| Braintree Laboratories, INC. | $67.53 | 2021-2025 | Suflave, Sutab |
| Conmed Corporation | $52.04 | 2022 | |
| Baxter Healthcare | $48.76 | 2025 | Floseal |
| Fresenius Kabi USA, LLC | $42.93 | 2023 | Idacio |
| Ethicon US, LLC | $42.71 | 2025 | Echelon; Endopath |
| Eisai INC. | $42.63 | 2020 | |
| Fujifilm Healthcare Americas Corporation | $33.92 | 2025 | |
| Sandoz INC. | $33.74 | 2023 | Hyrimoz |
| Redhill Biopharma INC. | $32.35 | 2021-2022 | |
| Acacia Pharma INC | $25.70 | 2021 | |
| Capsovision, INC. | $23.27 | 2024 | Capsocam Plus |
| Digestive Care, INC. | $21.41 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.25 | 2024 | Cyltezo |
| Shield Therapeutics INC | $18.45 | 2023 | Accrufer |
| Vertex Pharmaceuticals Incorporated | $15.87 | 2025 | |
| Novo Nordisk INC | $14.36 | 2025 | Wegovy |
| Alnylam Pharmaceuticals INC. | $13.26 | 2023 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niraj Jani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.